drugset / Trial / NCT00214851
The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria
Phase 1
Completed
8 enrolled
Nova Scotia Health Authority
Atlantic Provinces Dermatology Association · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
An open labelled trial of Kineret (anakinra) induction therapy (100mg./day) in over a four week period in the treatment of Familial Cold Urticaria. Familial Cold Urticaria (FCU) is a rare autosomal dominant condition manifesting symptoms triggered by exposure to cold and variable in expression. Currently there is no standard reliable agent available for the treatment of patients with FCU.This study will evaluate the efficacy of Kineret (anakinra), an interleukin 1 receptor antagonist in induction and maintenance therapy in patients with FCU.
Timeline
- Start
- 2005-09
- Primary completion
- 2005-12
- Completion
- 2005-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anakinra | Protein / enzyme biologic | 100 mg | Subcutaneous |